Corinne Johnson
Stock Analyst at Goldman Sachs
(3.37)
# 1,011
Out of 5,090 analysts
15
Total ratings
53.85%
Success rate
21.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MBX MBX Biosciences | Initiates: Sell | $18 | $31.45 | -42.77% | 1 | Dec 4, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $10 → $20 | $14.71 | +35.96% | 2 | Sep 16, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $20 → $24 | $20.11 | +19.34% | 2 | Sep 5, 2025 | |
| RNA Avidity Biosciences | Reinstates: Buy | $55 | $71.73 | -23.32% | 2 | Jul 10, 2025 | |
| AVBP ArriVent BioPharma | Reinstates: Buy | $33 | $25.15 | +31.21% | 3 | Jul 10, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $182 | $155.63 | +16.94% | 1 | Jul 10, 2025 | |
| CGON CG Oncology | Upgrades: Buy | $43 → $50 | $43.88 | +13.95% | 3 | May 14, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $22.73 | +119.97% | 1 | Mar 13, 2024 |
MBX Biosciences
Dec 4, 2025
Initiates: Sell
Price Target: $18
Current: $31.45
Upside: -42.77%
Amylyx Pharmaceuticals
Sep 16, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $14.71
Upside: +35.96%
Syndax Pharmaceuticals
Sep 5, 2025
Maintains: Buy
Price Target: $20 → $24
Current: $20.11
Upside: +19.34%
Avidity Biosciences
Jul 10, 2025
Reinstates: Buy
Price Target: $55
Current: $71.73
Upside: -23.32%
ArriVent BioPharma
Jul 10, 2025
Reinstates: Buy
Price Target: $33
Current: $25.15
Upside: +31.21%
Neurocrine Biosciences
Jul 10, 2025
Initiates: Buy
Price Target: $182
Current: $155.63
Upside: +16.94%
CG Oncology
May 14, 2024
Upgrades: Buy
Price Target: $43 → $50
Current: $43.88
Upside: +13.95%
Immunovant
Mar 13, 2024
Initiates: Buy
Price Target: $50
Current: $22.73
Upside: +119.97%